CD8A and neoplasm: These data demonstrate that intratumorally administered IL-7–CBD combined with CBD–IL-12 could boost systemic antitumoral immune response and inhibit pulmonary metastasis and could promote tumor-specific anamnestic response, especially tumor-specific CD8+ T cells, and prevent tumor regrowth.